promazine has been researched along with Alzheimer Disease in 23 studies
Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.
promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "promazine in the treatment of behavioral and psychological symptoms in dementia(BPSD)." | 2.71 | Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD). ( Cotroneo, A; De Sarro, G; Gareri, P; Lacava, R; Loiacono, A; Marigliano, N; Seminara, G, 2004) |
| "Alzheimer's disease is the most common cause of dementia." | 1.42 | In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier. ( Cahlíková, L; Chlebek, J; Hošt'álková, A; Opletal, L; Pérez, DI; Šafratová, M; Štěpánková, Š, 2015) |
| "Risperidone and promazine were the most frequently prescribed antipsychotic; 40." | 1.35 | Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units. ( Lucca, U; Matucci, M; Nobili, A; Pasina, L; Riva, E; Tarantola, M; Tettamanti, M; Trevisan, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 16 (69.57) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Marco-Contelles, J | 1 |
| León, R | 3 |
| de los Ríos, C | 1 |
| Samadi, A | 1 |
| Bartolini, M | 3 |
| Andrisano, V | 4 |
| Huertas, O | 2 |
| Barril, X | 1 |
| Luque, FJ | 3 |
| Rodríguez-Franco, MI | 6 |
| López, B | 3 |
| López, MG | 4 |
| García, AG | 3 |
| Carreiras, Mdo C | 1 |
| Villarroya, M | 4 |
| Camps, P | 1 |
| Formosa, X | 1 |
| Galdeano, C | 1 |
| Muñoz-Torrero, D | 3 |
| Ramírez, L | 1 |
| Gómez, E | 1 |
| Isambert, N | 1 |
| Lavilla, R | 2 |
| Badia, A | 1 |
| Clos, MV | 2 |
| Mancini, F | 2 |
| Arce, MP | 4 |
| Dafni, T | 1 |
| González-Muñoz, GC | 2 |
| Pérez, C | 4 |
| Conde, S | 3 |
| Romero, A | 1 |
| del Barrio, L | 1 |
| Martín-de-Saavedra, MD | 1 |
| Egea, J | 2 |
| Tang, H | 3 |
| Zhao, LZ | 1 |
| Zhao, HT | 2 |
| Huang, SL | 2 |
| Zhong, SM | 2 |
| Qin, JK | 1 |
| Chen, ZF | 2 |
| Huang, ZS | 2 |
| Liang, H | 2 |
| Chiriano, G | 1 |
| De Simone, A | 2 |
| Perez, DI | 2 |
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Legname, G | 1 |
| Martinez, A | 1 |
| Carloni, P | 1 |
| Roberti, M | 1 |
| Wang, ZY | 1 |
| Sun, Y | 2 |
| Chen, J | 1 |
| Chen, X | 1 |
| Huang, L | 3 |
| Li, X | 3 |
| Di Pietro, O | 1 |
| Pérez-Areales, FJ | 2 |
| Juárez-Jiménez, J | 1 |
| Espargaró, A | 2 |
| Pérez, B | 3 |
| Sabaté, R | 2 |
| Miao, H | 1 |
| Meng, F | 1 |
| Xie, SS | 1 |
| Wang, X | 1 |
| Jiang, N | 1 |
| Yu, W | 1 |
| Wang, KD | 1 |
| Lan, JS | 1 |
| Li, ZR | 1 |
| Kong, LY | 1 |
| Cahlíková, L | 1 |
| Štěpánková, Š | 1 |
| Chlebek, J | 1 |
| Šafratová, M | 1 |
| Hošt'álková, A | 1 |
| Opletal, L | 1 |
| Wei, S | 1 |
| Chen, W | 1 |
| Qin, J | 1 |
| Huangli, Y | 1 |
| Wang, L | 1 |
| Shen, Y | 1 |
| Xia, CL | 1 |
| Wang, N | 1 |
| Guo, QL | 1 |
| Liu, ZQ | 1 |
| Wu, JQ | 1 |
| Ou, TM | 1 |
| Tan, JH | 1 |
| Wang, HG | 1 |
| Li, D | 1 |
| Monjas, L | 1 |
| Gil, C | 1 |
| Hepnarova, V | 1 |
| Korabecny, J | 1 |
| Matouskova, L | 1 |
| Jost, P | 1 |
| Muckova, L | 1 |
| Hrabinova, M | 1 |
| Vykoukalova, N | 1 |
| Kerhartova, M | 1 |
| Kucera, T | 1 |
| Dolezal, R | 1 |
| Nepovimova, E | 1 |
| Spilovska, K | 1 |
| Mezeiova, E | 1 |
| Pham, NL | 1 |
| Jun, D | 1 |
| Staud, F | 1 |
| Kaping, D | 1 |
| Kuca, K | 1 |
| Soukup, O | 1 |
| Reis, J | 1 |
| Cagide, F | 1 |
| Valencia, ME | 1 |
| Teixeira, J | 1 |
| Bagetta, D | 1 |
| Uriarte, E | 1 |
| Oliveira, PJ | 1 |
| Ortuso, F | 1 |
| Alcaro, S | 1 |
| Borges, F | 1 |
| Hu, J | 1 |
| Pan, T | 1 |
| An, B | 1 |
| Li, Z | 1 |
| Turcu, AL | 2 |
| Barniol-Xicota, M | 1 |
| Pont, C | 1 |
| Pivetta, D | 1 |
| Sureda, FX | 2 |
| Vázquez, S | 2 |
| Companys-Alemany, J | 1 |
| Phillips, MB | 1 |
| Patel, DS | 1 |
| Griñán-Ferré, C | 1 |
| Loza, MI | 1 |
| Brea, JM | 1 |
| Soto, D | 1 |
| Kurnikova, MG | 1 |
| Johnson, JW | 1 |
| Pallàs, M | 1 |
| Nobili, A | 1 |
| Pasina, L | 1 |
| Trevisan, S | 1 |
| Riva, E | 1 |
| Lucca, U | 1 |
| Tettamanti, M | 1 |
| Matucci, M | 1 |
| Tarantola, M | 1 |
| Gareri, P | 1 |
| Cotroneo, A | 1 |
| Lacava, R | 1 |
| Seminara, G | 1 |
| Marigliano, N | 1 |
| Loiacono, A | 1 |
| De Sarro, G | 1 |
| Scoyni, RM | 1 |
| Aiello, L | 1 |
| Trani, I | 1 |
| Felli, B | 1 |
| Masin, AM | 1 |
| Camponi, V | 1 |
| Dignazio, L | 1 |
| Cortese, M | 1 |
| Pacitti, MT | 1 |
| Carratelli, D | 1 |
| Morocutti, C | 1 |
1 trial available for promazine and Alzheimer Disease
| Article | Year |
|---|---|
Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Brain; Diagnostic | 2004 |
22 other studies available for promazine and Alzheimer Disease
| Article | Year |
|---|---|
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholines | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cataly | 2009 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cel | 2011 |
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Aporphines; Blood- | 2011 |
A small chemical library of 2-aminoimidazole derivatives as BACE-1 inhibitors: Structure-based design, synthesis, and biological evaluation.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cell Surviv | 2012 |
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Binding Sites; Blood-Bra | 2012 |
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Electro | 2013 |
Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Dose-Response | 2014 |
Discovery of indanone derivatives as multi-target-directed ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; B | 2014 |
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzopyrans; Blood-Brain Barrier; Brain; Cell Survival; Cel | 2015 |
In Vitro Inhibitory Effects of 8-O-Demethylmaritidine and Undulatine on Acetylcholinesterase and Their Predicted Penetration across the Blood-Brain Barrier.
Topics: Acetylcholinesterase; Alzheimer Disease; Amaryllidaceae Alkaloids; Biological Transport; Blood-Brain | 2015 |
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Autophagy; Cholinesteras | 2016 |
Design, synthesis and evaluation of 2-arylethenyl-N-methylquinolinium derivatives as effective multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Death; Cell Line; | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Don | 2017 |
The concept of hybrid molecules of tacrine and benzyl quinolone carboxylic acid (BQCA) as multifunctional agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Line; Cholinesterase I | 2018 |
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug | 2018 |
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Aminopyridines; Animals; Benzamides; Clioquinol; Cyclic Nucleotide Phosphodiester | 2019 |
A novel class of multitarget anti-Alzheimer benzohomoadamantane‒chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors.
Topics: Acetylcholinesterase; Adamantane; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitor | 2019 |
Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Caenorhabditis elegans; Disease Models, Animal; Memantine; Mice; Recepto | 2022 |
Use and misuse of antipsychotic drugs in patients with dementia in Alzheimer special care units.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Antip | 2009 |
Drug adverse events and drop-out risk: a clinical case.
Topics: Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzothiazoles; Brain; Dopamine Agonists | 2007 |